Eisai °®¶¹“«Ć½ Release
/index.html
View the latest °®¶¹“«Ć½. news releases.Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
/news/2024/news202493.html
Eisai's news release Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases is posted. 2024-12-23T10:00:00+09:00āURECEĀ®ā (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA
/news/2024/news202492.html
Eisai's news release āURECEĀ®ā (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA is posted. 2024-12-11T08:30:00+09:00āLEQEMBIĀ®ā (Lecanemab) Approved for the Treatment of Early Alzheimerās Disease in Mexico
/news/2024/news202491.html
Eisai's news release āLEQEMBIĀ®ā (Lecanemab) Approved for the Treatment of Early Alzheimerās Disease in Mexico is posted. 2024-12-05T08:30:00+09:00Eisai Announces Completion of Cancellation of Treasury Shares
/news/2024/news202490.html
Eisai's news release Eisai Announces Completion of Cancellation of Treasury Shares is posted. 2024-11-29T15:30:00+09:00āLEQEMBIĀ®ā (Lecanemab) for the Treatment of Alzheimerās Disease Launched in South Korea
/news/2024/news202489.html
Eisai's news release āLEQEMBIĀ®ā (Lecanemab) for the Treatment of Alzheimerās Disease Launched in South Korea is posted. 2024-11-28T08:30:00+09:00EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE āAD-DMT REGISTRYā IN JAPAN
/news/2024/news202488.html
Eisai's news release EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE āAD-DMT REGISTRYā IN JAPAN is posted. 2024-11-26T08:30:00+09:00ROZEBALAMINĀ® FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN
/news/2024/news202487.html
Eisai's news release ROZEBALAMINĀ® FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN is posted. 2024-11-20T08:30:10+09:00ANTICANCER AGENT āTASFYGOĀ® TABLETS 35mgā (TASURGRATINIB SUCCINATE) LAUNCHED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION OR REARRANGEMENTS
/news/2024/news202486.html
Eisai's news release ANTICANCER AGENT āTASFYGOĀ® TABLETS 35mgā (TASURGRATINIB SUCCINATE) LAUNCHED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION OR REARRANGEMENTS is posted. 2024-11-20T08:30:00+09:00NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT)
/news/2024/news202485.html
Eisai's news release NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT) is posted. 2024-11-15T08:30:00+09:00Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimerās Disease
/news/2024/news202484.html
Eisai's news release Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimerās Disease is posted. 2024-11-15T01:00:00+09:00Eisaiās Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMEDās āStrengthening Program for Pharmaceutical Startup Ecosystemā
/news/2024/news202483.html
Eisai's news release Eisaiās Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMEDās āStrengthening Program for Pharmaceutical Startup Ecosystemā is posted. 2024-11-05T08:30:00+09:00Eisai Completes Rolling Submission to US FDA for LEQEMBIĀ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimerās Disease Under the Fast Track Status
/news/2024/news202482.html
Eisai's news release Eisai Completes Rolling Submission to US FDA for LEQEMBIĀ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimerās Disease Under the Fast Track Status is posted. 2024-11-01T08:30:00+09:00Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimerās Disease (CTAD) Conference
/news/2024/news202481.html
Eisai's news release Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimerās Disease (CTAD) Conference is posted. 2024-10-31T08:30:00+09:00EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
/news/2024/news202480.html
Eisai's news release EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) is posted. 2024-10-31T08:30:00+09:00REVENUE OF LEQEMBIĀ® (PRELIMINARY BASIS)
/news/2024/news202479.html
Eisai's news release REVENUE OF LEQEMBIĀ® (PRELIMINARY BASIS) is posted. 2024-10-30T19:45:00+09:00